Compounded Semaglutide vs Ozempic and Wegovy: What's Actually Different

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

The comparison between compounded semaglutide and the branded FDA-approved products Ozempic and Wegovy is the question most patients ask first and the question most often answered poorly online. The honest answer requires acknowledging both what these products share and what they do not. They share an active pharmaceutical ingredient. They do not share regulatory status, manufacturing oversight, supply chain, formulation excipients, or the body of clinical trial evidence directly testing the specific preparation a patient is receiving.

This page explains those differences in plain language. It is written for patients who have been on Ozempic or Wegovy and are considering switching to compounded semaglutide, for patients who started with compounded and are wondering whether to switch to a branded product, and for patients trying to make a first-time decision. It is also relevant for patients trying to understand why their compounded semaglutide costs less than a Wegovy coupon-discounted price and what that price difference does and does not mean.

For background on what compounded semaglutide is and how it is dispensed, see the pillar guide.

The Shared Active Ingredient

Ozempic, Wegovy, and compounded semaglutide all contain semaglutide as the active pharmaceutical ingredient. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed and patented by Novo Nordisk. It is a single molecule with a well-characterized structure, a well-characterized pharmacology, and a well-characterized mechanism of action.

When the same active ingredient is administered at the same dose to the same patient via the same route, the pharmacological effect is the same. This is the basic principle that allows clinicians to prescribe compounded preparations of medications that share an active ingredient with an FDA-approved product. The compounded preparation is not a different drug. It is the same drug in a different finished form.

This is the framing that compounded semaglutide and Wegovy share the same active ingredient. It is accurate and it is important. It is also not the entire picture.

What Is Different

Ozempic and Wegovy are FDA-approved finished pharmaceutical products manufactured by Novo Nordisk in tightly controlled facilities under current Good Manufacturing Practice (cGMP) regulations. Each batch is tested for identity, purity, potency, sterility, and bioavailability against specifications filed with the FDA. The finished products are dispensed in pre-filled pens with specific excipients (sodium acetate trihydrate, propylene glycol, phenol, sodium chloride, and water for injection in Ozempic, with similar excipient profiles in Wegovy).

Compounded semaglutide is prepared by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities. The active ingredient is sourced as an active pharmaceutical ingredient (API) from a registered supplier. The compounding pharmacy combines the API with appropriate excipients and prepares the finished product under USP 797 standards for sterile compounding. The finished product is dispensed in vials, often at a concentration set by the prescription, and is administered with a separately supplied syringe.

The regulatory framework is different. The manufacturing oversight is different. The finished form is different. The excipients may be different depending on the pharmacy.

What is not different is the active ingredient itself, when sourced from a properly registered supplier and verified for identity and purity through pharmacy testing.

Why the FDA Allowed Compounding During the Shortage and What Changed

The FDA placed Wegovy on its drug shortage list in March 2022 and Ozempic in August 2022. Both shortages were driven by demand that exceeded Novo Nordisk's manufacturing capacity. While a drug is on the FDA shortage list, federal law allows 503A and 503B pharmacies to compound preparations that are essentially copies of the FDA-approved product, which is otherwise prohibited.

In October 2024 the FDA initially declared the semaglutide shortage resolved. The status was subsequently challenged in court and the agency reissued guidance permitting continued compounding under specific circumstances, including clinical need not met by the commercial product. The legal landscape continues to evolve. As of mid-2026, compounded semaglutide remains available through LegitScript-certified providers under clinical need pathways that document patient-specific factors justifying the compounded preparation.

The regulatory situation matters for patients because it affects supply continuity. A patient starting on compounded semaglutide should understand that the regulatory framework is more dynamic than the framework for branded products, and ongoing access depends on continued legal availability of the compounding pathway. Reputable providers monitor this situation actively and communicate changes to patients.

For a deeper analysis of the regulatory framework, see our supporting article on the 503A and 503B regulatory framework.

Comparing Clinical Outcomes

The clinical trial evidence for semaglutide weight loss outcomes comes from trials of Wegovy. STEP-1 reported 14.9 percent mean weight loss at 2.4 mg over 68 weeks. STEP-3 reported 16.0 percent with combined intensive behavioral therapy. STEP-4 demonstrated the importance of continued therapy. SELECT established cardiovascular risk reduction at the same dose.

Compounded semaglutide has not been studied in trials of the same scale because the compounded preparation is not a single standardized product, and trials are typically designed around standardized products. Patients on compounded preparations report outcomes broadly consistent with the published trial data when they are on equivalent doses and titration schedules, but the published evidence base for the specific compounded preparation a given patient receives is limited.

This is the most honest framing. The active ingredient is the same. The trial data on the active ingredient at the relevant dose is solid. The trial data on the specific finished compounded preparation a given patient receives is not. Patients who value the security of having direct trial data on their exact preparation should choose the FDA-approved product. Patients who are comfortable with the pharmacological reasoning that the same active ingredient at the same dose produces the same effect, and who have a reason to prefer the compounded preparation, may reasonably choose the compounded option.

Reasons Patients Choose Compounded Over Branded

The clinical situations in which compounded semaglutide is selected over the branded product include:

The patient has documented clinical need that the commercial product does not meet. This is the regulatory baseline. Examples include dose requirements that fall between the available branded pen doses, ingredient allergies or sensitivities to excipients in the commercial product, or specific clinical situations where a customized preparation is appropriate.

The patient does not have insurance coverage for the branded product and the cash price of the branded product is prohibitive. This is the most common practical reason. A patient without coverage facing a $1,349 monthly cash price for Wegovy may instead use compounded semaglutide at approximately $179 to $399 monthly through a LegitScript-certified provider.

The patient is on Medicare and is excluded from Part D coverage of weight-loss medications under current federal statute. This affects a significant population of patients with obesity who would otherwise be appropriate candidates for therapy.

For more on cost considerations, see our cluster hub on cost and access.

Reasons Patients Choose Branded Over Compounded

There are equally good reasons to choose the FDA-approved product when access and cost permit.

The patient has commercial insurance that covers Wegovy or Ozempic with a manageable copay. In this situation, the branded product is almost always the right choice. The patient is paying less out of pocket and receiving the product with the most direct trial evidence.

The patient values the regulatory certainty of an FDA-approved finished product over the more dynamic compounded framework. This is a reasonable preference and one that some patients prioritize highly.

The patient has experienced injection-site issues with a compounded preparation and wants to try the standardized pen-injector form factor. The Wegovy pen is a pre-filled, single-use device with a fixed dose, which some patients prefer over vial-and-syringe administration.

The patient has had inconsistent experience with a specific compounded preparation and wants the lot-to-lot consistency of a single manufacturer's product. This is a real consideration. Some compounding pharmacies are more consistent than others.

Switching Between Compounded and Branded

Switching between compounded and branded semaglutide, in either direction, is clinically straightforward when done at the same dose. The active ingredient is the same. The pharmacological behavior is the same.

The practical considerations are administrative rather than clinical. The patient needs a new prescription written to the appropriate product. Insurance coverage and prior authorization may need to be re-established. The injection technique differs slightly because the branded products use pre-filled pens and compounded products typically use vials and syringes.

The week of the switch should be the week of a normally scheduled dose. There is no washout period required. The next dose, at the new product, is given on the regular schedule.

For step-by-step switching guidance, see our supporting article on switching from Wegovy to compounded semaglutide.

What to Ask Before Choosing

Whether you are starting therapy for the first time or considering a switch, the questions to ask are the same.

What does the clinician recommend for my specific clinical situation, and what is the reasoning?

What is the total monthly cost, and is the price the same in month two as in month one?

What is the dose, the concentration, and the titration schedule?

Where is the medication being compounded or manufactured, and is the pharmacy licensed in my state?

Is the provider LegitScript-certified?

What happens if I have side effects, need a dose hold, or need to pause therapy?

What is the plan for the lab monitoring before and during therapy?

What happens if the regulatory or supply landscape changes for compounded preparations?

These questions are not meant to be confrontational. They are the questions a good clinic will be glad to answer and that establish a baseline for the therapeutic relationship.

This hub is part of the Compounded Semaglutide vs Ozempic and Wegovy cluster. Related supporting articles include:

For the foundational overview, return to the pillar guide.

Not FDA-approved. HealthRX is not a medical practice. Information on this site is for educational purposes and is not a substitute for individualized medical advice. Treatment decisions are made between you and a licensed clinician. Compounded semaglutide is dispensed by state-licensed 503A pharmacies and FDA-registered 503B outsourcing facilities under individual prescriptions. Ozempic and Wegovy are registered trademarks of Novo Nordisk. References: STEP-1 (Wilding et al., NEJM 2021), STEP-3 (Wadden et al., JAMA 2021), STEP-4 (Rubino et al., JAMA 2021), SELECT (Lincoff et al., NEJM 2023), SUSTAIN program.

This HealthRX guide is educational and is not a prescription, diagnosis, or substitute for care from a licensed clinician. Compounded semaglutide is not FDA-approved. Treatment decisions should be made with a prescriber who has reviewed your medical history.